New Search

If you are not happy with the results below please do another search

1122 search results for:

161

Yamaha Motor sets up new company to better analyse antibodies in blood

Yamaha Motor Co., Ltd. has established Tuning Fork Bio Inc. in Delaware, USA, which will analyze the antibodies in blood to better visualize people’s health conditions through its antibody profiling business. The main target markets for this new company are the U.S. and Japan.

162

Merck to pay Daiichi Sankyo up to $22bn to collaborate on 3 new cancer drugs

In a deal potentially worth up to US$22 billion, Merck (known as MSD outside of the United States and Canada) has entered into a collaboration agreement with Japan-based Daiichi Sankyo to co-develop and co-commercialize three of Daiichi Sankyo’s DXd antibody-drug conjugate (ADC) candidates: patritumab deruxtecan (HER3-DXd), ifinatamab deruxtecan (I-DXd) and raludotatug deruxtecan (R-DXd).

163

Improving equity of diagnosis of ovarian cancer

Although the prevalence of ovarian cancer is fairly low, it is often asymptomatic until after metastasis, resulting in it being the fourth leading cause of cancer death in females in the USA. The development of biomarker screening tests for ovarian cancer has been challenging and the situation is still not satisfactory. Additionally, the tests that […]

165

Utility of human chorionic gonadotropin as a tumour marker

By Rosa Ferrer, Andrea Mansilla and Maria Costa The role of human chorionic gonadotropin in pregnancy has been extensively studied for many years. However, the importance of this hormone goes beyond pregnancy. It can also be used as a biomarker, mainly in trophoblastic tumours, but as will be shown later in this article, its importance […]